Aquestive Therapeutics Inc. (NASDAQ:AQST)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
AQST Weekly Chart

Old Forum Content for AQST

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • spmeyers: @issues $CLSD $ARAV $APLT $AQST $MDXG $OXFD $MLSS these Rocket Ship stocks are very risky, gotta watch them like a hawk or you can lose a lot very fast
  • issues: Looking to buy one or more of these biotechs (IBD group 3!) : $CLSD $ARAV $APLT $AQST $MDXG $OXFD $MLSS
  • gwenzee: @issues $CLSD $ARAV $APLT $AQST $MDXG $OXFD $MLSS I'd start to pare this list down by eliminating all stocks under $10/share. Usually stocks are penny stocks for reason. Betting on them is a good way of losing your $$$.
  • issues: @gwenzee $CLSD $ARAV $APLT $AQST $MDXG $OXFD $MLSS Thank you Gwen! I like your advice!
  • Wolf: #Earnings - not much. $AQST Up 10% on new drug application.
  • indigo1948: @debeers $TXG - good morning. Are you still holding $AQST?
  • debeers: $AQST-Aquestive Therapeutics confirms FDA approval for Exservan Oral Film for the treatment of amyotrophic lateral sclerosis (ALS), an orphan disease. 8:04 AM ET, 11/25/2019 - Briefing.com "We received full FDA approval for Exservan in advance of our PDUFA action date. We appreciate the ongoing feedback from the FDA and its early-action approval. We anticipate that Exservan, via our orally administered PharmFilm dosage form, will bring meaningful treatment to patients who are diagnosed with ALS and face difficulties swallowing or administering traditional forms of medication," said Keith J. Kendall, Chief Executive Officer of Aquestive. "In line with our stated objectives, we licensed this product to Zambon S.p.A. for development and commercialization in the EU. We are continuing the dialogue with potential licensees for the US commercial rights." LONG-Miracle drug approval
  • debeers: $ARWR/$ATKRForgot to mention-Baird raised the price of the stock to 70 from 49 BEFORE earnings. So, ask yourself this, why in the world would any analyst (even the dumb ones) risk looking like an idiot and give an estimate now, instead of waiting for the call after market close today? Arrowhead is the real goods. as is $AQST.
Visit the Trading Forum to join in the discussion.
Stock Price $4.34
Change 5.85%
Volume 2,074,320

Request Video of AQST
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!